These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

680 related items for PubMed ID: 19581769

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R.
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine.
    Kobayashi M, Suzuki F, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Yatsuji H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Miyakawa Y, Kumada H.
    J Med Virol; 2007 Oct; 79(10):1472-7. PubMed ID: 17705186
    [Abstract] [Full Text] [Related]

  • 5. Long-term therapeutic efficacy of lamivudine compared with interferon-alpha in children with chronic hepatitis B: the younger the better.
    Choe BH, Lee JH, Jang YC, Jang CH, Oh KW, Kwon S, Hyun MC, Ko CW, Lee KS, Lee WK.
    J Pediatr Gastroenterol Nutr; 2007 Jan; 44(1):92-8. PubMed ID: 17204960
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW, Wong GL, Tsang SW, Hui AY, Chim AM, Yiu KK, Chan HY, Chan FK, Sung JJ, Chan HL.
    Antivir Ther; 2008 Jan; 13(4):571-9. PubMed ID: 18672536
    [Abstract] [Full Text] [Related]

  • 9. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.
    Fung J, Lai CL, Tanaka Y, Mizokami M, Yuen J, Wong DK, Yuen MF.
    Am J Gastroenterol; 2009 Aug; 104(8):1940-6; quiz 1947. PubMed ID: 19455108
    [Abstract] [Full Text] [Related]

  • 10. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
    Miailhes P, Trabaud MA, Pradat P, Lebouché B, Chevallier M, Chevallier P, Zoulim F, Trepo C.
    Clin Infect Dis; 2007 Sep 01; 45(5):624-32. PubMed ID: 17682999
    [Abstract] [Full Text] [Related]

  • 11. [The HBeAg/antiHBe seroconversion as a result of lamivudine treatment in children with chronic hepatitis B unresponsive to previous interferon alpha therapy].
    Lebensztejn DM, Skiba E, Sobaniec-Lotowska M, Kaczmarski M.
    Pol Merkur Lekarski; 2004 Jun 01; 16(96):557-9. PubMed ID: 15510896
    [Abstract] [Full Text] [Related]

  • 12. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
    Zhu M, Xu B, Yao GB.
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul 01; 13(7):534-6. PubMed ID: 16042894
    [Abstract] [Full Text] [Related]

  • 13. Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety.
    Jonas MM, Little NR, Gardner SD, International Pediatric Lamivudine Investigator Group.
    J Viral Hepat; 2008 Jan 01; 15(1):20-7. PubMed ID: 18088241
    [Abstract] [Full Text] [Related]

  • 14. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
    Yalçin K, Değertekin H, Kokoğlu OF, Ayaz C.
    Turk J Gastroenterol; 2004 Mar 01; 15(1):14-20. PubMed ID: 15264116
    [Abstract] [Full Text] [Related]

  • 15. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group.
    Chien RN, Liaw YF, Atkins M.
    Hepatology; 1999 Sep 01; 30(3):770-4. PubMed ID: 10462384
    [Abstract] [Full Text] [Related]

  • 16. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
    Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H.
    Gastroenterology; 2007 Nov 01; 133(5):1437-44. PubMed ID: 17983800
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B.
    Shin JW, Park NH, Park JH, Park JH, Jeong ID, Bang SJ, Joo KR, Kim DH.
    J Viral Hepat; 2005 Jul 01; 12(4):393-7. PubMed ID: 15985010
    [Abstract] [Full Text] [Related]

  • 18. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B.
    Sokal EM, Kelly DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, Vegnente A, Little NR, Gardener SD, Jonas MM.
    Hepatology; 2006 Feb 01; 43(2):225-32. PubMed ID: 16440364
    [Abstract] [Full Text] [Related]

  • 19. [Efficacy of lamivudine in patients with hepatitis B e antigen-negative chronic liver diseases].
    Jeong Id, Park NH, Kim BC, Park JH, Seo KW, Kim DH, Joo KR, Kim DH.
    Taehan Kan Hakhoe Chi; 2003 Jun 01; 9(2):69-78. PubMed ID: 12824746
    [Abstract] [Full Text] [Related]

  • 20. Durability of serologic response after lamivudine treatment of chronic hepatitis B.
    Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S, Schiff E.
    Hepatology; 2003 Apr 01; 37(4):748-55. PubMed ID: 12668966
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.